{"groups":[{"description":"Plerixafor 160mg/kg/dose by IV on days 5-8\n\nFilgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.","id":"FG000","title":"Plerixafor"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"39"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"39"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"One participant was deemed ineligible and is excluded from all analyses per study design.","recruitmentDetails":"Forty (40) participants were recruited at Mayo Clinic (Rochester, Florida and Arizona) between December 2009 and October 2011."}